<DOC>
	<DOCNO>NCT00631865</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety autologous transplantation melanocytes patient vitiligo .</brief_summary>
	<brief_title>Autologous Transplantation Melanocytes Treatment Vitiligo Skin</brief_title>
	<detailed_description>Vitiligo pigmentation disorder white patch skin appear different part body . Histologically characterize absence melanocyte along epidermal basal layer . Using cell suspension non-cultured melanocyte inject blister depigmented lesion , success rate 85 % report repigmentation . However limitation technique : induction blister limit several site body , hypo-pigmentation around recipient area due cryodamage peripheral melanocyte leakage suspension blister . To reduce problem , study inject melanocytes directly epidermis . A shaved biopsy specimen ( 1 cm2 ) take patient ` normally pigment area local anesthesia ( lidocaine hydrochloride 20 mg/ml ) . The specimen incubate 0.25 % trypsin solution 15 minute 37°C 0.02 % EDTA solution 10 minute . Then epidermal sheet gently manipulate forceps dissociate epidermal cell yield cell suspension , follow treatment 0.5 % trypsin/versene solution 37C 3-5 minute . Well-dispersed cell suspension aspirate 1 ml syrinx inject directly epidermis .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<criteria>Age 12 year Stable form vitiligo ( increase size lesion least one year ) No use immunosuppressive &amp; cytotoxic drug least past 6 month Pregnant patient Patients active disease Infection recipient site Evidence köebner past Keloidal tendency</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>melanocyte</keyword>
</DOC>